SOURCE: Tulip BioMed, Inc.

July 10, 2007 08:28 ET

Mark Glasgold, M.D., F.A.C.S., Joins Tulip BioMed's Board of Scientific Advisors

SAN DIEGO, CA--(Marketwire - July 10, 2007) - Tulip BioMed™, Inc. (PINKSHEETS: TPBD), a developer of biodesign instruments for living tissue management, including instruments for plastic, cosmetic, and orthopedic surgeries, announced today that Dr. Mark Glasgold has joined its Board of Scientific Advisors (BOSA).

Tulip BioMed's BOSA comprises some of the world's leading plastic and cosmetic surgeons: Robert W. Alexander, M.D., D.M.D., F.I.C.S., Robert A. Ersek, M.D., F.A.C.S., J. William Little, M.D., F.A.C.S., Thomas F. Mitts, M.D., Robert E. Peters, Ph.D., M.D., F.A.A.F.P, Oscar M. Ramirez, M.D., F.A.C.S., Luiz S. Toledo, M.D., and Woffles T.L. Wu, M.B., B.S., F.R.C.S., F.A.M.S. Brief biographies of the BOSA members are available at: www.tulipbiomed.com/corporate/corporate_about_team.html.

"We are honored that Mark has joined our Board of Scientific Advisors," stated John Johnson, Tulip's Chairman and CEO. "I have had the distinct privilege of working with all of the BOSA members, including Mark, over a period of many years. We appreciate the value that members of our Board of Scientific Advisors place on Tulip products, and we think that this is both positive and important not only for us, but the peers of our BOSA members as well."

Dr. Glasgold is board-certified in facial plastic surgery by the American Board of Facial Plastic & Reconstructive Surgery, and in head and neck surgery by the American Board of Otolaryngology-Head and Neck Surgery. He is a principal in the Glasgold Group Plastic Surgery (www.glasgoldgroup.com). He is an internationally recognized expert in the rejuvenation of the aging face, specifically facial fat transfer and facelift. Dr. Glasgold is a frequent lecturer on facial fat transfer and plastic surgery throughout the country, and led the first Facial Fat Transfer Workshop at the American Academy of Facial Plastic Surgery's 40th anniversary meeting in 2004. Dr. Glasgold has distinguished himself as a premier medical author, having written numerous articles and publications on facial plastic surgery. Along with fellow surgeons Samuel M. Lam and Robert A. Glasgold, he co-authored "Complementary Fat Grafting" (2006, Lippincott, Williams & Wilkins, publishers).

Dr. Glasgold is an alumnus of Duke University in Durham, NC, where he received a Bachelor of Arts, and the Thomas Jefferson Medical School in Philadelphia, where he received his M.D. In 1994 he received a Masters in Biomedical Engineering from UMDNJ-Robert Wood Johnson Medical School in Piscataway, NJ, where he also did a residency in general surgery, followed by a residency in head and neck surgery at Manhattan Eye, Ear, and Throat Hospital, Memorial Sloan-Kettering Cancer Center, the New York Hospital, and Cornell University. He then did a fellowship in facial plastic and reconstructive surgery under the auspices of the American Academy of Facial and Plastic Reconstructive Surgery (AAFPRS). For the past 10 years Dr. Glasgold has practiced at the Glasgold Group Plastic Surgery, and is an attending physician at Robert Wood Johnson University Hospital, in New Brunswick, NJ, and the Manhattan Eye, Ear & Throat Hospital in New York City. He is also a clinical assistant professor of surgery at UMDNJ-Robert Wood Johnson Medical School. In addition, he has served as a resident instructor at the Manhattan Eye, Ear & Throat Hospital. Currently he is a co-director of the Facial Plastic Surgery Fellowship Program of the AAFPRS.

Tulip BioMed's products, and additional information about the company, can be accessed at www.tulipdisposables.com. Doctors and industry professionals who would like to discuss the many advantages of Tulip BioMed's products are encouraged to call the company at 800-978-8547.

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • CONTACT:
    Premier Funding Service
    Kelly Black
    President
    Email Contact

    Heather Kerwin
    Investor Relations
    Email Contact

    (480) 649-8224 Office
    (480) 898-0406 Fax